Find Nitroaspirin manufacturers, exporters & distributors on PharmaCompass

Nitroaspirin

Suanfarma, at the Core of a Better Life.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 175033-36-0, Ncx-4016, No-aspirin 1, Ncx 4016, [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate, No-asa

Molecular Formula

C₁₆H₁₃NO₇

Molecular Weight

331.28 g/mol

InChI Key

IOJUJUOXKXMJNF-UHFFFAOYSA-N

FDA UNII

EH04H13L6B

Nitric Oxide-Releasing Acetylsalicylic Acid Derivative is a nitric oxide (NO) donating derivative of acetylsalicylic acid with anti-inflammatory, analgesic, antipyretic, antithrombotic, gastroprotective and potential antitumor activities. The acetylsalicylic acid derivative moiety of this agent inhibits the activities of cyclooxygenase (COX) I and II, preventing the formation of prostaglandins and thromboxanes. A reduction in prostaglandin synthesis accounts for this agent's anti-inflammatory, anti-pyretic and analgesic activities; a reduction in thromboxane A2 synthesis results in an irreversible inhibition of platelet aggregation. NO donation by this agent, after cleavage from the acetylsalicylic acid derivative in vivo, may protect the gastric mucosa against the damaging effects of the aspirin derivative by modulating prostaglandins. In tumor cells, the NO donating moiety may block the cell cycle in the G1 and G2 phases and may induce apoptosis through caspase-mediated mechanisms.

1 2D Structure

Nitroaspirin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate

2.1.2 InChI

InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3

2.1.3 InChI Key

IOJUJUOXKXMJNF-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]

2.2 Other Identifiers

2.2.1 UNII

EH04H13L6B

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl Ester

2. Ncx 4016

3. Ncx-4016

4. Nitric Oxide-releasing Aspirin

2.3.2 Depositor-Supplied Synonyms

1. 175033-36-0

2. Ncx-4016

3. No-aspirin 1

4. Ncx 4016

5. [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate

6. No-asa

7. 3-((nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate

8. Eh04h13l6b

9. Benzoic Acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl Ester

10. 3-[(nitrooxy)methyl]phenyl 2-(acetyloxy)benzoate

11. M-no-asa

12. Benzoic Acid, 2-(acetyloxy)-, 3-[(nitrooxy)methyl]phenyl Ester

13. 3-(nitroxymethyl)phenyl 2-acetoxybenzoate

14. M-no-aspirin

15. Nitric Oxide-releasing Aspirin

16. 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl Ester

17. 2-((nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate

18. 2-acetoxybenzoic Acid 3-nitrooxymethylphenyl Ester

19. Unii-eh04h13l6b

20. Benzoic Acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl Ester

21. Schembl19524

22. Chembl374385

23. Gtpl9018

24. Zinc22315

25. Dtxsid60938618

26. Ncx4016

27. Chebi:125482

28. Bcp24321

29. Benzoic Acid,2-(acetyloxy)-, 3-[(nitrooxy)methyl]phenyl Ester

30. Akos025294730

31. Ccg-208118

32. Db12445

33. Hy-123823

34. 3-((nitrooxy)methyl)phenyl2-acetoxybenzoate

35. Cs-0086219

36. Ft-0673020

37. Ncx 4016, >=98% (hplc)

38. 3-((nitrooxy)methyl)phenyl 2-acetoxybenzoate

39. 2-acetoxy Benzoic Acid-3-nitrooxymethyl Phenyl Ester

40. J-011058

41. Q3877377

42. Brd-k08807999-001-01-6

43. 2-(acetyloxy)-(3-(nitroxymethyl)phenyl)benzoic Acid

44. (2-{[(1s)-1-(5-fluoro(2-pyridyl))ethyl]amino}-5-chloropyrimidin-4-yl)[5-(methylethoxy)pyrazol-3-yl]amine

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₃NO₇
Molecular Weight	331.28 g/mol
XLogP3	2.9
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Exact Mass	331.06920175 g/mol
Monoisotopic Mass	331.06920175 g/mol
Topological Polar Surface Area	108 Å²
Heavy Atom Count	24
Formal Charge	0
Complexity	462
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

Cysteine Proteinase Inhibitors

Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)

Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

Fibrinolytic Agents

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)

ABOUT THIS PAGE

Nitroaspirin Manufacturers

A Nitroaspirin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nitroaspirin, including repackagers and relabelers. The FDA regulates Nitroaspirin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nitroaspirin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Nitroaspirin Suppliers

A Nitroaspirin supplier is an individual or a company that provides Nitroaspirin active pharmaceutical ingredient (API) or Nitroaspirin finished formulations upon request. The Nitroaspirin suppliers may include Nitroaspirin API manufacturers, exporters, distributors and traders.

Nitroaspirin GMP

Nitroaspirin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Nitroaspirin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nitroaspirin GMP manufacturer or Nitroaspirin GMP API supplier for your needs.

Nitroaspirin CoA

A Nitroaspirin CoA (Certificate of Analysis) is a formal document that attests to Nitroaspirin's compliance with Nitroaspirin specifications and serves as a tool for batch-level quality control.

Nitroaspirin CoA mostly includes findings from lab analyses of a specific batch. For each Nitroaspirin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Nitroaspirin may be tested according to a variety of international standards, such as European Pharmacopoeia (Nitroaspirin EP), Nitroaspirin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nitroaspirin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.